Abstract
Four patients with deep mycoses were treated with itraconazole. Two patients had chromoblastomycosis, one patient each had aspergillosis and Rhinofacial zygomycosis. These patients were either resistant to or showed poor response to Amphotericin B and/or ketoconazole. After the initial clinical and mycological evaluation, itraconazole was given in a daily dose of 200 mg orally. All patients responded to the drug very well. No adverse effects attributable to itraconazole were detected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marichal P, Gorrens J, Vandeu Bossche H. The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus niger. J Med Vet Mycol 1984; 22: 13–21.
Espinel-Ingroff A, Shadomy S, Gebhert RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother 1984; 26: 5–9.
Renning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive Aspergillosis with itraconazole. Am J Med 1989; 86: 791–800.
Lavalle P, Suchil P, De Ovando F, Reynoso S. Itraconazole for deep mycoses. Preliminary experience in Mexico. Rev Infect Dis 9 Suppl. 1: 564–70.
Tucker PM, Williams PL, Arathoon EG, Stevens DA. Treatment of mycoses with itraconazole. Annals New York Academy of Sciences 1988; 544: 451–70.
Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 1987; 91 (Suppl. 1): 557–63.
Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. Philadelphia: WB Saunders, 1988.
Restrepo A, Gonzalez A, Gomez I, Arango M, De Bedont C. Treatment of chromomycoses with itraconazole. Annals New York Academy of Sciences 1988; 544: 504–16.
Phillips P, Fetchick R, Weisman I, Foshee S, Granybill JR. Tolerance to and efficacy of itraconazole in treatment of systemic mycoses: preliminary results. Rev Infect Dis 1987; 9: 587–93.
Craner A, Arathoon E, Stevens DA. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev. Infect Dis 1987; 9 (Suppl. 1): 77–86.
Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically and parenterally administered itraconazole with treatment of superficial and deep mycoses: Animal models. Rev Infect Dis 1987; 9 (Suppl. 1): 515–32.
Van Cutsem J, Van Gervea F, Van De Ven MA, Borgers M, Janssen PA. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob. Agents Chemother 1984; 26: 527–34.
Sharkey PK, Rinaldi MG, Lerner CJ, Fetchick RJ, Dernn JF, Graybill JR: High dose itraconazole in the treatment of severe mycoses (Abstract 575). In: Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society of Microbiology, 1988: 210.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kumar, B., Kaur, I., Chakrabarti, A. et al. Treatment of deep mycoses with itraconazole . Mycopathologia 115, 169–174 (1991). https://doi.org/10.1007/BF00462221
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00462221